Navigation Links
Sulonex in Medical News

Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann

...ERX ) announced today that the Company and Alfa Wassermann S.p.A. have settled a dispute over issues arising from the terminated license agreement for sulonex (sulodexide). Under the terms of the settlement agreement, Alfa Wassermann is paying Keryx US$3,500,000 (of which US$2,750,000 has already been receiv...

Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results

...income (loss) was primarily attributable to a $25,894,000 decrease in research and development expenses related to the cessation of the development of sulonex in March 2008, a $2,671,000 and $344,000 decrease in research and development expenses related to KRX-0401 and Zerenex, respectively, a $3,128,000 inc...

Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results

...e in net loss was primarily attributable to a $11,699,000 decrease in research and development expenses related to the cessation of the development of sulonex in March 2008, a $1,860,000 decrease in expenses related to our other clinical compounds, and a $519,000 decrease in non-cash compensation expense rel...

Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results

...e in net loss was primarily attributable to a $10,390,000 decrease in research and development expenses related to the cessation of the development of sulonex in March 2008, an $852,000 decrease in expenses related to our other clinical compounds, a $567,000 decrease in non-cash compensation expense related ...
Sulonex in Medical Technology

Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial

...sed on a review of the available proteinuria data, sulonex did not appear to be different than placebo. The s...here can be no assurance that the results from the sulonex Phase 3 and/or Phase 4 study will track the data f...he DiNAS Phase 2 study. Results from these earlier sulonex studies may not be indicative of results from futu...

Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint

...sults from its SUN-MICRO Phase 3 clinical trial of sulonex (sulodexide) for the treatment of diabetic nephrop...here can be no assurance that the results from the sulonex Phase 3 study will track the data from the pilot C...he DiNAS Phase 2 study. Results from these earlier sulonex studies may not be indicative of results from futu...

Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial

...A filing before year end. "The completion of the sulonex Phase 3 clinical program is an important and signi...d analyzing the data from this study." ABOUT THE sulonex (sulodexide oral gelcap) PHASE 3 and PHASE 4 CLINI...e of the filing of the NDA for sulodexide. ABOUT sulonex (sulodexide oral gelcap) Sulodexide belongs to a...

Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data

...rial. The DSMC raised no safety concerns regarding sulonex or the trial. As planned, no review was conducted ...SULONEX(TM) PHASE 3 and PHASE 4 CLINICAL PROGRAM sulonex is in a pivotal Phase 3 and Phase 4 clinical progr...ling of the NDA for Sulonex. ABOUT SULONEX(TM) sulonex (sulodexide oral gelcap) belongs to a proposed new...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois

...rael, New York, NY ABOUT SULONEX(TM) sulonex (sulodexide oral gelcap) belongs to a proposed new...es in which the kidneys are progressively damaged. sulonex is a glycosaminoglycan compound with structural si...n excretion in patients with diabetic nephropathy. sulonex is in a pivotal Phase III and Phase IV clinical pr...

Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia

...s KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Ker...
Sulonex in Biological Technology

Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results

...cash from a settlement with the former licensor of sulonex (sulodexide). The Company will receive an additio...ses related to the cessation of the development of sulonex in March 2008. The net income for the six m...ses related to the cessation of the development of sulonex in March 2008, a $4.4 million decrease in research...

Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results

...rch and development expenses related to the cessation of the development of sulonex in March 2008, a $7,013,000 and $2,735,000 decrease in research and develop...rch and development expenses related to the cessation of the development of sulonex in March 2008, a $8,165,000 and $1,401,000 decrease in research and develop...

Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results

... cessation of our development of Sulonex. Such costs included an $11,037,000 non-cash impairment charge related to the write-down of the assets of the sulonex manufacturing suite to their estimated fair value, and a $2,063,000 provision for estimated costs relating to the required restoration of the manufact...

Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan

...17 million, and is primarily related to the completion and shut-down of the sulonex clinical program and restructuring costs. Additional elements of the Comp... severance benefits and a non-cash write-off of the assets of the Company's sulonex manufacturing facility. As part of the workforce reduction, the position ...

Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint

...sults from its SUN-MICRO Phase 3 clinical trial of sulonex (sulodexide) for the treatment of diabetic nephrop...here can be no assurance that the results from the sulonex Phase 3 study will track the data from the pilot C...he DiNAS Phase 2 study. Results from these earlier sulonex studies may not be indicative of results from futu...

Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results

... and development expenses related to the Company's sulonex pivotal Phase 3 and Phase 4 clinical program, a $6...iew of the safety and efficacy data related to the sulonex Phase 3 trial, at which time the DSMC again found ...r ability to finalize the new drug application for sulonex before year-end, even if we receive positive resul...

Keryx Biopharmaceuticals Announces Additions to Management Team

...o build the corporate infrastructure to manage both the potential launch of sulonex and the future development and commercialization of our other drug candidat...o differ materially are the following: the results of the Phase 3 study for sulonex could be inconclusive or negative; even if we receive positive results from...

Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results

...,000 increase in research and development expenses related to the Company's sulonex pivotal Phase III and Phase IV clinical program, a $3,834,000 increase in e...lue of our product portfolio. We continue to stay focused on completing the sulonex clinical development program, with data from our Phase III study expected i...
Other Tags
(Date:2/27/2015)... 2015 Hispanics develop alcoholic liver disease ... and 12 years earlier than Whites/Caucasians or African Americans, ... System. , While previous research indicated that Hispanics tend ... new study -- published online in the journal Alcoholism: ... the first to pinpoint racial and ethnic disparities in ...
(Date:2/27/2015)... OnChip Devices , a world ... wire bondable, silicon ESD (Electrostatic Discharge) protection diodes targeted ... ESD88NP and ESD88PN are designed ... and IC products. These Zeners exhibit no device ... devices meet the requirements of IEC61000 and safely dissipate ...
(Date:2/27/2015)... Beverly Hills, CA (PRWEB) February 27, 2015 ... was in the air for those suffering from Sjögren’s ... had been discovered by researchers at the University of ... the next phase of research was to develop a ... to precisely detect the presence of new autoantibodies. Researchers ...
(Date:2/27/2015)... FL (PRWEB) February 27, 2015 Today, February ... KAJ Brothers , along with LXR Organics ... the END IT Campaign to raise awareness and promote prevention, ... to statistics provided by the END IT Coalition, slavery is ... per year and exists in 167 countries around the world. ...
(Date:2/27/2015)... Clinovo, a leading provider of cloud-based ... Capture (EDC) at the CALBIO2015 conference taking ... March 3rd at Booth # 141. , ... and edit-check builder allowing Clinical Trials Managers to create ... without any programming experience. Clinovo’s new pricing model offers ...
Breaking Medicine News(10 mins):Health News:UC Davis Study Finds Hispanics Develop Alcoholic Liver Disease at Younger Ages than Caucasians or African Americans 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3Health News:Breakthrough Blood Test for Early Detection of Sjögren’s Syndrome Now Available 2Health News:KAJ Brothers Join the Campaign to 'End It - Shine A Light On Slavery' 2Health News:Clinovo to Demo Its Self-Service, Cloud-Based EDC Solution at CALBIO2015 on March 2nd and 3rd, 2015 2
(Date:2/12/2015)... Feb. 12, 2015   MedNet Solutions , ... clinical study management systems, has recently bolstered its ... distinguishing iMedNet as the ... (CROs) and healthcare consultants.  Building on the Program,s ... referrals and numerous co-marketing opportunities), MedNet,s new and ...
(Date:2/10/2015)... Feb. 10, 2015  Alere Inc. (NYSE: ALR), ... financial results for the quarter ended December 31, ... and President of Alere said, "We made substantial ... as the global leader in rapid diagnostics and ... Alere Health divestiture in early January enabled us ...
(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35
Other Contents